Panzyga® has a maximum
infusion rate of 8 mg/kg/min
for cITP in adults1

Dosing and Rate of Administration for Adult Patients With cITP1

Dose

2 g/kg

2 daily doses
of 1 g/kg

(10 mL/kg given on 2 consecutive days)

Initial Infusion Rate

(first 30 minutes)

1 mg/kg/min

(0.01 mL/kg/min)

Maximum Infusion Rate

(as tolerated)

8 mg/kg/min

(0.08 mL/kg/min)

The initial infusion rate should be maintained for 30 minutes. If tolerated, the infusion rate may be gradually increased every 15 to 30 minutes after the initial infusion to a maximum of 8 mg/kg/min (0.08 mL/kg/min) as tolerated.1

Download Panzyga® cITP Dosing Chart

Patient Weight mL/hr
<span>In kg</span>
<span>In lb</span>
<span>First 30 minutes</span><br>(0.01 mL/kg/min)
<span>Next 15-30 minutes</span><br><em>if previous rate tolerated</em><br>(0.02 mL/kg/min)
<span>Next 15-30 minutes</span><br><em>if previous rate tolerated</em><br>(0.04 mL/kg/min)
<span>Next 15-30 minutes</span><br><em>if previous rate tolerated</em><br>(0.08 mL/kg/min)
<span>Maximum</span><br><em>if previous rate tolerated</em><br>(0.12 mL/kg/min)

Example Ramp-Up Schedule for an 80 kg Adult Patient with cITP

Total Panzyga® Infusion Time for an Adult Patient with cITP1


Recommended ramp-up infusion rate if previous rate is tolerated

  • Panzyga® should be started at 1 mg/kg/min and continued at the infusion rates stated here, if tolerated.1
  • The example shown above follows a ramp-up of 1, 4, and 8 mg/kg/min.
  • For patients at risk of renal dysfunction or thromboembolic events, administer panzyga® at the minimum infusion rate practicable. Do not exceed 3.3 mg/kg/min (0.033 mL/kg/min). Discontinue if renal function deteriorates.1

Example for 80-kg patient with cITP:

2 g/kg total dose divided into
2 daily doses

Panzyga® Infusion Rate Chart for cITP

Patient Weight
mL/hr

In kg

In lb

First 30 minutes
(0.01 mL/kg/min)

Next 15-30 minutes
if previous rate tolerated
(0.04 mL/kg/min)

Maximum
if previous rate tolerated
(0.08 mL/kg/min)
40 88 24 96 192
45 99 27 108 216
50 110 30 120 240
55 121 33 132 264
60 132 36 144 288
65 143 39 156 312
70 154 42 168 336
75 165 45 180 360
80 176 48 192 384
85 187 51 204 408
90 198 54 216 432
95 209 57 228 456
100 220 60 240 480
105 231 63 252 504
110 242 66 264 528
115 253 69 276 552
120 264 72 288 576
125 276 75 300 600
130 287 78 312 624
135 298 81 324 648
140 309 84 336 672
Download Panzyga® cITP Dosing Chart
  • 2 g/kg divided into 2 daily doses of 1 g/kg (10 mL/kg) given on 2 consecutive days1
  • The initial infusion rate should be maintained for 30 minutes. Following the initial infusion, and if tolerated, the infusion rate may be gradually increased every 15 to 30 minutes, as tolerated, to the maximum infusion rate of 8 mg/kg/min (0.02 mL/kg/min)1

Patient Weight mL/hr
In kg In lb First 30 minutes
(0.01 mL/kg/min)		 Next 15-30 minutes
if previous rate tolerated
(0.02 mL/kg/min)		 Next 15-30 minutes
if previous rate tolerated
(0.04 mL/kg/min)		 Maximum
if previous rate tolerated
(0.12 mL/kg/min)

CITP = chronic immune thrombocytopenia.

Reference: 1. Panzyga®. Prescribing information. Octapharma USA, Inc.; 2021.

Indications & Important Safety Information
for panzyga® Immune Globulin Intravenous (Human) – IFAS 10% Liquid Preparation

Please click here for Full Prescribing Information, including BOXED WARNING.

  • Thrombosis may occur with immune globulin intravenous (IVIg) products, including panzyga®. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
  • Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients who receive IVIg products, including panzyga®. Patients predisposed to renal dysfunction include those with a degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IVIg products containing sucrose. Panzyga® does not contain sucrose.
  • For patients at risk of thrombosis, renal dysfunction, or acute renal failure, administer panzyga® at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

See Full Prescribing Information, Warnings and Precautions (5.2, 5.4)

Indications and Usage

Panzyga® (Immune Globulin Intravenous [Human] – ifas) is indicated for the treatment of primary humoral immunodeficiency (PI) in patients 2 years of age 
and older; this includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies; chronic immune thrombocytopenia (cITP) in adults to raise platelet counts to control or prevent bleeding; and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults to improve neuromuscular disability and impairment.

Contraindications

Panzyga® is contraindicated in patients who have a history of severe systemic hypersensitivity reactions, such as anaphylaxis, to human immunoglobulin and in IgA-deficient patients with antibodies against IgA and history of hypersensitivity.

Warnings and Precautions

  • Monitor renal function, including blood urea nitrogen and serum creatinine, and urine output in patients at risk of developing acute renal failure.
  • Hyperproteinemia, increased serum osmolarity, and hyponatremia may occur in patients receiving panzyga®.
  • Aseptic meningitis syndrome may occur in patients receiving panzyga®, especially with high doses or rapid infusion.
  • Hemolysis that is either intravascular or due to enhanced red blood cell sequestration can develop subsequent to panzyga® treatments. Risk factors for hemolysis include high doses and non-O-blood group. Closely monitor patients for hemolysis and hemolytic anemia.
  • Monitor patients for pulmonary adverse reactions (transfusion-related acute lung injury [TRALI]).
  • Monitor blood pressure prior to, during, and following panzyga® infusion.
  • Carefully consider the relative risks and benefits before prescribing the high dose regimen (for cITP) in patients at increased risk of volume overload.
  • Panzyga® is made from human plasma and may contain infectious agents, e.g. viruses and theoretically, the Creutzfeldt-Jakob disease agent.

Adverse Reactions

  • PI – The most common adverse reactions reported in greater than 5% of subjects were: headache, nausea, fever, fatigue, and abdominal pain.
  • cITP in adults – The most common adverse reactions reported in greater than 5% of subjects were: headache, fever, nausea, vomiting, dizziness, and anemia.
  • CIDP in adults – The most common adverse reactions reported in greater than 5% of subjects were: headache, fever, dermatitis, and blood pressure increase.

The risk information provided here is not comprehensive; See full Prescribing Information and Boxed Warning for panzyga®.

To report suspected adverse reactions, contact Octapharma USA, Inc. at 1-866-766-4860 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

You are now leaving panzygausa.com

Octapharma does not review, endorse, or control the content of any non-Octapharma site. Octapharma is not responsible for the accuracy, content, practices, or standards of any non-Octapharma resources accessed through a link on this site. Octapharma provides general information for educational purposes. This site does not provide medical advice, diagnosis, or treatment to you. Always consult your physician to help decide a treatment plan or other medical advice.